Immunotherapy cocktail targets tough blood cancers

NCT ID NCT01592370

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug nivolumab (Opdivo), alone or combined with other drugs, in 320 people with relapsed or refractory non-Hodgkin lymphoma, Hodgkin lymphoma, or multiple myeloma. The main goal was to check safety and side effects, especially for the nivolumab plus daratumumab combination. Researchers also looked at how well the tumors responded. The trial has completed, and results help guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo), alone or combined with ipilimumab, lirilumab, daratumumab, pomalidomide, or dexamethasone
What this could lead to: If successful, this could point toward new treatment options for patients with hard-to-treat blood cancers like lymphoma and multiple myeloma.
What could go wrong: This is an early-phase trial focused on safety, not a proven treatment. Results may not lead to a standard therapy, and side effects can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA MULTIPLE MYELOMA NON-HODGKIN'S LYMPHOMA

Contacts and locations

Locations

Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Division Of Hematology & Oncology Ctr. For Health Sciences

Los Angeles, California, 90095, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Huntsman Cancer Institute At The Univ. Of Utah

Salt Lake City, Utah, 84112, United States
John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States
Local Institution

Yvoir, B-5530, Belgium
Local Institution

Bologna, 40138, Italy
Local Institution

Chorzów, 41-500, Poland
Local Institution - 0001

New York, New York, 10065, United States
Local Institution - 0002

Rochester, Minnesota, 55905, United States
Local Institution - 0003

Baltimore, Maryland, 21231, United States
Local Institution - 0004

Philadelphia, Pennsylvania, 19111, United States
Local Institution - 0005

Salt Lake City, Utah, 84112, United States
Local Institution - 0006

Portland, Oregon, 97239, United States
Local Institution - 0007

Philadelphia, Pennsylvania, 19104, United States
Local Institution - 0009

Boston, Massachusetts, 02215, United States
Local Institution - 0011

Ann Arbor, Michigan, 48109, United States
Local Institution - 0012

Los Angeles, California, 90095, United States
Local Institution - 0014

Hackensack, New Jersey, 07601, United States
Local Institution - 0015

Boston, Massachusetts, 02215, United States
Local Institution - 0017

Aurora, Colorado, 80045, United States
Local Institution - 0018

Westwood, Kansas, 66205, United States
Local Institution - 0019

Indianapolis, Indiana, 46202, United States
Local Institution - 0023

Orlando, Florida, 32804, United States
Local Institution - 0028

Columbus, Ohio, 43210, United States
Local Institution - 0033

Omaha, Nebraska, 68130, United States
Local Institution - 0035

Clovis, California, 93611, United States
Local Institution - 0037

Skokie, Illinois, 60077, United States
Local Institution - 0039

Athens, 11528, Greece
Local Institution - 0040

Poznan, 61-848, Poland
Local Institution - 0042

Wroclaw, 50-367, Poland
Local Institution - 0043

Poitiers, Vienne, 86021, France
Local Institution - 0044

Nantes, 44000, France
Local Institution - 0045

Ghent, 9000, Belgium
Local Institution - 0047

Sint-Niklaas, 9100, Belgium
Local Institution - 0049

Warsaw, 02-776, Poland
Local Institution - 013

New Haven, Connecticut, 06520, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
OHSU Center for Hematologic Malignancies

Portland, Oregon, 97239, United States
The Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21231, United States
University Of Michigan Health System

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.